# Eylea Post Marketing Surveillance(PMS)

> **NCT01783925** · — · COMPLETED · sponsor: **Bayer** · enrollment: 3206 (actual)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

## Key facts

- **NCT ID:** NCT01783925
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-29
- **Primary completion:** 2018-12-31
- **Final completion:** 2018-12-31
- **Target enrollment:** 3206 (ACTUAL)
- **Last updated:** 2023-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01783925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01783925, "Eylea Post Marketing Surveillance(PMS)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT01783925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*